Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seritage Growth PropertiesSRG · Entity 9015 | Director | March 31, 2021 | April 01, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seritage Growth Properties
Report date March 31, 2021 · Filed April 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common SharesSEC Table I · non-derivative | Direct | 5,450 |
Reported balance
After 2021-03-31 transaction · row 1
1 source rowRow 1 · 2021-03-31 · Purchase · Acquired 5,450 · Balance 5,450 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2021 Filed Apr 1, 2021 23:39 UTC | Seritage Growth Properties SRG · Entity 9015 | PurchaseClass A Common Shares | 5,450 | $18.04 | $98,318.00 |
DisclosureSEC source: 0000895345-21-000419 · form4.xml · nonDerivative · entry 1 Thrush Allison · CIK 0001774397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,450 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.